
|Videos|October 11, 2017
Dr. Loeb on the Impact of Additional Testing for Prostate Cancer
Author(s)Stacy Loeb, MD
Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.
Advertisement
Stacy Loeb, MD, assistant professor of Urology and Population Health at NYU Langone Health's Perlmutter Cancer Center, discusses the impact of different genomic tests for patients with prostate cancer.
Patients now have more testing options than before, states Loeb. Patients no longer need to rely on a single biopsy, as there are multiple tests which will help physicians determine the most beneficial treatment and management options for the patient.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
Adjuvant CDK4/6 Inhibitors Gain Ground as Oral SERDs Emerge to Tackle Endocrine Resistance in Early HR+ Breast Cancer
3
Sofi-Cel Earns FDA Breakthrough Therapy Designation in Heavily Pretreated R/R T-ALL and T-LBL
4
Mezigdomide-Based Triplet Highlights Potential of CELMoDs in Myeloma Management
5

























































































